Abstract 15053: Prevalence and Clustering of Cardiovascular Risk Factors Across the National Income Spectrum in the Africa Middle East Region
Background: Developing countries account for a large proportion of global deaths from cardiovascular disease (CVD). Macroeconomic factors may exacerbate the burden of CVD in these countries. We evaluated CVD risk factor (CVDRF) prevalence in the Africa and Middle East (AfME) region according to national income categories.
Methods: The Africa Middle East Cardiovascular Epidemiological (ACE) Study is a multinational cross-sectional study evaluating the prevalence of CVDRFs (hypertension, diabetes mellitus, dyslipidemia, obesity, smoking and abdominal obesity) in stable adult outpatients attending 94 general practice clinics across 14 countries in the AfME region. Countries were classified using World Bank definitions into low-income (LI), lower-middle income (LMI), upper-middle income (UMI), and high-income (HI) groups.
Results: In total, 4,378 patients were recruited [age 46 ±14 years, 52% female, 260 (6%) from LI countries, 1,324 (30%) from LMI countries, 1,509 (35%) from UMI countries, and 1,285 (29%) from HI countries]. Dyslipidemia was the most prevalent risk factor, reported in > 2/3rd of the population across the 4 national income categories. The prevalence of diabetes, obesity (BMI ≥ 30 kg/m2) and smoking increased with higher national incomes reaching 32%, 44%, and 16%, respectively in HI countries. Abdominal obesity was reported in at least ~ 2/3rd of the cohort across national income levels. CVDRFs tended to cluster with half (53%) of the overall cohort having ≥ 3 CVDRFs. CVDRF clustering (≥ 3 CVDRFs) was more prevalent with higher national income, ranging from 33% in LI countries to 57% in HI countries.
Conclusions: CVDRFs are widely prevalent across the national income spectrum in the AfME region. Higher income countries have a larger burden of diabetes, obesity and smoking, and a higher prevalence of CVDRF clustering. Economic development should be coupled with aggressive public health measures to limit the associated increase in CVDRF burden.
Author Disclosures: A.A. Alsheikh-Ali: Other Research Support; Modest; Medtronic. Honoraria; Modest; Pfizer, Bayer, Boehringer Ingelheim. M.I. Omar: Employment; Significant; Employee of Pfizer Inc. F.J. Raal: Research Grant; Modest; Amgen, Sanofi/Regeneron for clinical trials with PCSK9 inhibitors. Speakers Bureau; Modest; Amgen, Sanofi/Regeneron, Pfizer, AstraZeneca. Honoraria; Modest; Amgen, Sanofi/Regeneron, Pfizer, AstraZeneca. Consultant/Advisory Board; Modest; Amgen, Sanofi/Regeneron, Pfizer, AstraZeneca. W. Rashed: None. O. Hamoui: Speakers Bureau; Modest; Algorithm, AstraZeneca, Boehringer Ingelheim, Novartis, Sanofi, Servier. Honoraria; Modest; Algorithm, AstraZeneca, Boehringer Ingelheim, Novartis, Sanofi, Servier. A. Kane: None. M. Alami: None. P. Abreu: Employment; Significant; Employee of Pfizer Inc. W.M. Mashhoud: Employment; Significant; Employee of Pfizer Inc.
- © 2014 by American Heart Association, Inc.